home > news > detailed info

Saneca to drive R&D Initiative following €1.5 million funding

Saneca Pharma

Slovaki-based CDMO pushes forward with new R&D initiatives for the manufacture of APIs

Contract development and manufacturing organisation (CDMO) Saneca Pharma is driving forward with new research and development initiatives for the manufacture of active pharmaceutical ingredients (APIs) following a €1.5 million grant from the Slovak Ministry of Education, Science, Research and Sport.

The funding has enabled the central-Europe based company to strengthen its pharmaceutical development services and establish a new R&D department, with 25 employees now based at its facility in Hlohovec, Slovakia.

Saneca Pharma received the four-year grant in partnership with organic synthesis specialist, TAU-CHEM Ltd. The two companies have now embarked on complementary research projects that will serve to strengthen Slovakia’s pharmaceutical industry.

The CDMO’s initiatives include laboratory research for the preparation of APIs, with a particular focus on chiral molecules and emphasis on the principles of sustainable development and ‘green chemistry’. As part of this, the company will look at energy efficient production methods and the use of renewable raw materials.

Using the team’s opiate development and manufacturing expertise, combined with the technical agility afforded by the breadth of technologies available on site, the CDMO will also explore abuse resistant techniques for finished dosage forms.

Jan Batka, API sales director at Saneca Pharma, said: “The funding has enabled us to accelerate our R&D strategy by creating a specialist team and applying our know-how in bringing new generic molecules and intermediates into our portfolio.

“There are a number of advantages that can be realised through partnering with a Slovakia-based CDMO, including the highly skilled workforce, central European location and competitive pricing. It’s great to receive additional support from the state to help grow the country’s pharmaceutical industry to its full potential.”

Jan continued: “In 2017 we plan to double our annual R&D expenditure in this area, creating broader research opportunities that will enable us to achieve a competitive advantage in the global pharmaceutical market.”

Based in western Slovakia, with close proximity to Vienna, Saneca Pharma develops and manufactures a variety of finished dosage forms, with strong capabilities in solids and semi-solids and specialist expertise in the development of opiate APIs and finished dosage forms from farm to pharmacy.
phone +421 33 736 1111
email Nitrianska 100, 920 27 Hlohovec, Slovak Republic, Slovakia
Print this page
Send to a friend
News and Press Releases

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. This latest extension includes grants from MJFF to support two projects:
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement